Ascendis Pharma A/S Clinical And Quality-Of-Life Data For TransCon PTH-Treated Adults With Chronic Hypoparathyroidism To Be Presented At ECE 2024
Ascendis Pharma A/S Clinical And Quality-Of-Life Data For TransCon PTH-Treated Adults With Chronic Hypoparathyroidism To Be Presented At ECE 2024
Ascendis Pharma A/S (NASDAQ:ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefits in adult patients with chronic hypoparathyroidism will be presented at the European Congress of Endocrinology being held May 11-14, 2024, in Stockholm.
Ascendis Pharma A/S（纳斯达克股票代码：ASND）今天宣布，支持成年慢性甲状旁腺功能减退患者临床和生活质量益处的新TransCon PTH（palopegteriparatide）数据将在2024年5月11日至14日在斯德哥尔摩举行的欧洲内分泌学大会上公布。
Topics include an oral presentation of new 2-year results from a post-hoc analysis of the Phase 3 PaTHway Trial demonstrating sustained improvements in kidney function in adults with chronic hypoparathyroidism treated with TransCon PTH, as well as a symposium presentation on health and quality-of-life improvements in patients switching from rhPTH(1-84) to TransCon PTH as part of a compassionate use program.
主题包括口头介绍对3期PathWh试验进行事后分析的2年新结果，该研究表明接受TransCon PTH治疗的慢性甲状旁腺功能减退的成年人的肾功能持续改善，以及关于作为同情使用计划的一部分从rHPTH（1-84）转为TransCon PTH的患者的健康和生活质量改善的研讨会演讲。
"We are pleased to partner with leading experts in endocrinology to present this new, groundbreaking data showing the health and quality-of-life benefits of initiating or switching to TransCon PTH treatment," said Aimee Shu, M.D., Ascendis Pharma's Senior Vice President of Clinical Development, Endocrine Medical Sciences.
Ascendis Pharma内分泌医学临床开发高级副总裁Aimee Shu医学博士表示：“我们很高兴与内分泌学领域的领先专家合作，展示了启动或改用TransCon PTH治疗对健康和生活质量的好处。”
The full schedule of Ascendis presentations during ECE 2024 follow:
腾飞在2024年欧洲经委会期间的演讲的完整时间表如下：
| Sunday, May 12 2:50 pm (2:40 pm session) Rooms A2-A3 |
Oral Presentation Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 2-Year Results from the Phase 3 PaTHway Trial Dr. Peter Schwarz |
| Monday, May 13 12:40 – 1:55 pm Room A7 |
Symposium
|
| 5 月 12 日星期日 下午 2:50 （下午 2:40 会议） 房间 A2-A3 |
口头演讲 使用Palopegteriparatide持续改善患有慢性甲状旁腺功能减退的成年人的肾功能：3期Pathway试验的2年结果 彼得·施瓦兹博士 |
| 5月13日星期一 下午 12:40 — 1:55 A7 房间 |
座谈会
|